索拉非尼
鉴定(生物学)
计算生物学
药品
药物靶点
药物发现
化学
激酶
药理学
癌症研究
生物
生物化学
肝细胞癌
植物
作者
Li Yang,Qingshi Meng,Ping Wang,Xiaolei Liu,Qiuyu Fu,Yuting Xie,Yu Zhou,Xiangbing Qi,Niu Huang
标识
DOI:10.1101/2020.05.06.079947
摘要
Abstract The identification of unknown target of a multi-kinase inhibitor sorafenib is important to better understand the mechanism of action of this drug in anti-cancer and anti-fibrotic treatments. Here, we report the combination of PROTAC technique with quantitative proteomic analysis to identify the unknown cellular targets of sorafenib. Sorafenib-based PROTAC can strongly degrade a non-kinase target PDEδ in different types of cells. We also confirmed the direct binding interaction of PDEδ with sorafenib by CETSA and SPR assays. Together, our research suggests that PDEδ is a new potential target of sorafenib, and PROTAC technology may be a promising approach for cellular target identification of bioactive compounds of interest.
科研通智能强力驱动
Strongly Powered by AbleSci AI